Hypoxia Stress Response Pathways: Modeling and Targeted Therapy
暂无分享,去创建一个
Aniruddha Datta | Sriram Sridharan | Rajani Varghese | Vijay Venkatraj | A. Datta | Sriram Sridharan | Rajani Varghese | Vijay Venkatraj
[1] C. Andreani,et al. Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by inhibition of bone morphogenetic protein signaling. , 2014, Cellular signalling.
[2] Shailendra Giri,et al. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK , 2014, Proceedings of the National Academy of Sciences.
[3] P. Goodwin,et al. Understanding the benefit of metformin use in cancer treatment , 2011, BMC medicine.
[4] Aleksander S. Popel,et al. Reactive Oxygen Species Regulate Hypoxia-Inducible Factor 1α Differentially in Cancer and Ischemia , 2008, Molecular and Cellular Biology.
[5] G. Semenza,et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.
[6] J. Mackey,et al. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer , 2008, British Journal of Cancer.
[7] Bin Xu,et al. Colorectal Cancer Cells Refractory to Anti-VEGF Treatment Are Vulnerable to Glycolytic Blockade due to Persistent Impairment of Mitochondria , 2013, Molecular Cancer Therapeutics.
[8] G. Melillo,et al. Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy , 2006, Molecular Cancer Research.
[9] W. Wilson,et al. Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.
[10] R. Weinmann,et al. Enhancer element at the 3'-flanking region controls transcriptional response to hypoxia in the human erythropoietin gene. , 1991, The Journal of biological chemistry.
[11] Joon Young Choi,et al. Synergistic Anti-Cancer Effect of Phenformin and Oxamate , 2014, PloS one.
[12] Alfonso Bellacosa,et al. Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways , 2005, Oncogene.
[13] Murtaza M Tambuwala,et al. A dynamic model of the hypoxia-inducible factor 1&agr; (HIF-1&agr;) network , 2013, Journal of Cell Science.
[14] G. Semenza,et al. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. , 1998, The American journal of physiology.
[15] Aniruddha Datta,et al. Introduction to Genomic Signal Processing with Control , 2006 .
[16] J. Lévesque,et al. Targeting the Hypoxia‐Sensing Pathway in Clinical Hematology , 2014, Stem cells translational medicine.
[17] C. Hoppel,et al. Ischemic defects in the electron transport chain increase the production of reactive oxygen species from isolated rat heart mitochondria. , 2008, American journal of physiology. Cell physiology.
[18] S. Choe,et al. BMPs and their clinical potentials. , 2011, BMB reports.
[19] Aniruddha Datta,et al. From biological pathways to regulatory networks , 2010, CDC.
[20] Michael I. Wilson,et al. C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.
[21] G. Semenza. Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.
[22] R. Bristow,et al. Tumor hypoxia as a driving force in genetic instability , 2013, Genome Integrity.
[23] Mire Zloh,et al. Targeting Glycolysis: A Fragment Based Approach Towards Bifunctional Inhibitors of hLDH-5. , 2011 .
[24] G. Semenza,et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[25] S. Colowick,et al. The role of glycolysis in the growth of tumor cells. II. The effect of oxamic acid on the growth of HeLa cells in tissue culture. , 1961, The Journal of biological chemistry.
[26] G. Powis,et al. Hypoxia inducible factor-1alpha as a cancer drug target. , 2004, Molecular cancer therapeutics.
[27] P. Schumacker,et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. , 2005, Cell metabolism.
[28] Xin Yu,et al. 3-Bromopyruvic acid, a hexokinase II inhibitor, is an effective antitumor agent on the hepatoma cells : in vitro and in vivo findings. , 2014, Anti-cancer agents in medicinal chemistry.
[29] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[30] Steven O Simmons,et al. Cellular stress response pathway system as a sentinel ensemble in toxicological screening. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.
[31] Debby Laukens,et al. Pharmacologic activation of tumor hypoxia: a means to increase tumor 2-deoxy-2-[18F]fluoro-D-glucose uptake? , 2013, Molecular imaging.
[32] Mark A. Schroeder,et al. Targeting Src Family Kinases Inhibits Bevacizumab-Induced Glioma Cell Invasion , 2013, PloS one.
[33] N. Denko,et al. Hypoxia, HIF1 and glucose metabolism in the solid tumour , 2008, Nature Reviews Cancer.
[34] Giuseppe Cicero,et al. Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines , 2013, BioMed research international.
[35] Marianne Koritzinsky,et al. Translational control of gene expression during hypoxia , 2006, Cancer biology & therapy.
[36] P. ten Dijke,et al. BMP signaling in vascular diseases , 2012, FEBS letters.
[37] G. Semenza,et al. HIF-1 and human disease: one highly involved factor. , 2000, Genes & development.
[38] A. Datta,et al. Boolean modeling and fault diagnosis in oxidative stress response , 2012, BMC Genomics.
[39] A. Levine,et al. The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes , 2010, Science.
[40] N. Chandel,et al. Reactive Oxygen Species Generated at Mitochondrial Complex III Stabilize Hypoxia-inducible Factor-1α during Hypoxia , 2000, The Journal of Biological Chemistry.